Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanFRA:L74 -4.46%55 EBIT per Share is €0.17 as of Dec. 2025. GuruFocus rates FRA:L74 with a GF Score™ of 55/100. The stock has 3 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 98.18% on this metric.
WuXi XDC Cayman's EBIT per Share for the
six
months ended in Dec. 2025 was €0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.17.
During the past 12 months, the average EBIT per Share Growth Rate of WuXi XDC Cayman was 77.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 118.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 119.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for WuXi XDC Cayman's EBIT per Share or its related term are showing as below:
FRA:L74'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 118.2 Med: 131.2 Max: 133.2
Current: 118.2
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of WuXi XDC Cayman was 133.20% per year. The lowest was 118.20% per year. And the median was 131.20% per year.
FRA:L74's 3-Year EBIT Growth Rate is ranked better than 98.18% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.6
vs FRA:L74: 118.20
WuXi XDC Cayman's EBIT for the
six
months ended in Dec. 2025 was €106.6 Mil.
WuXi XDC Cayman (FRA:L74) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
WuXi XDC Cayman EBIT per Share Related Terms
WuXi XDC Cayman EBIT per Share Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (FRA:L74) has a EBIT per Share of €0.17 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on WuXi XDC Cayman and its competitors. According to the industry distribution chart, WuXi XDC Cayman ranks #3 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 1.8%.
Is WuXi XDC Cayman's EBIT per Share too high?
WuXi XDC Cayman's current EBIT per Share is €0.17. Based on the distribution chart, WuXi XDC Cayman ranks #3 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #3 out of 165 companies for EBIT per Share. This places WuXi XDC Cayman in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.60, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current EBIT per Share is €0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (FRA:L74) has a current EBIT per Share of €0.17. The current EBIT per Share is €0.17. WuXi XDC Cayman's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For WuXi XDC Cayman (FRA:L74), the current EBIT per Share is €0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
55GF Score
Get the complete analysis for FRA:L74
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L74 has been successfully added to your 
